4 Vaccine Stocks To Look Out For Right Now
Given the current rise in coronavirus concerns amongst investors, vaccine stocks could be worth eyeing in the stock market today. After all, vaccines remain one of the most prominent lines of defense against the coronavirus pandemic now. We can see this shift in focus towards vaccine stocks as some of the hottest reopening stocks take a breather. Take Norwegian Cruise Line (NYSE: NCLH) and Expedia Group (NASDAQ: EXPE) for instance. Both companies’ shares are currently down by over 9% in the past month. Given all of this, I can understand the appeal for vaccine stocks now.
Not to mention, some of the newer variants of concern (VoCs) appear to be more effective against first-generation vaccines. Because of this, vaccine frontrunners such as AstraZeneca (NASDAQ: AZN) are actively reviewing the need for booster shots. Meanwhile, Aside from that, Dr. Anthony Fauci also provided a positive update on the current vaccines in use. Over the weekend, Fauci said that he was hopeful of the Food and Drug Administration (FDA) giving vaccines full approvals by the end of August. This would see three of the names in our list today getting bumped up from emergency-use status. All in all, could these top vaccine stocks in the stock market now be wise investments?
Best Vaccine Stocks To Buy [Or Avoid] In August 2021
- Novavax Inc. (NASDAQ: NVAX)
- Moderna Inc. (NASDAQ: MRNA)
- Johnson & Johnson (NYSE: JNJ)
- Pfizer Inc. (NYSE: PFE)
Novavax Inc.
Novavax is a biotechnology company that is developing and commercializing innovative vaccines to prevent serious infectious diseases. The company’s proprietary recombinant technology platform combines the best aspects of genetic engineering to efficiently produce highly immunogenic nanoparticles that can meet global health needs. The company is currently conducting late-stage clinical trials for its vaccine candidate against the coronavirus. NVAX stock currently trades at $208.48 as of 12:13 p.m. ET.
Last week, the company announced that it will need to address the concerns of federal regulators, which want Novavax to strengthen its testing and quality control operations. This minor setback should not discourage investors as the company is at the last leg of its vaccine race. It also provided operational highlights last week in its second-quarter financials.
Notably, it has filed regulatory submissions for emergency use authorization (EUA) in India, Indonesia, and the Philippines in partnership with Serum Institute of India. It also said that its vaccine candidate has cross-reactive functional antibodies to the Delta variant that is currently raging around the world. Given the exciting news surrounding the company, will you consider buying NVAX stock?
Read More
Moderna Inc.
Moving on, we have Moderna, an enterprise with a diverse clinical portfolio of vaccines and therapeutics across many modalities. With its platform, the company develops technologies that enable the development of mRNA medicines for diverse applications. Notably, its modalities include cancer vaccines and localized regenerative therapeutics among others. MRNA stock is up over 11% during Monday morning’s trading session and currently trades at $459.90 as of 9:43 a.m. ET. Last week, the company reported its second-quarter fiscal year 2021 financial results and also provided a crucial business update.
Diving in, the company noted that its final blinded analysis of its Phase 3 COVE study shows 93% efficacy. Its vaccine’s efficacy also remains durable through six months after the second dose. Its booster candidate also demonstrated robust antibody responses to the variants of concern in Phase 2. Moderna also says that its coronavirus vaccine candidate for the pediatric population ages 6 months to 11 years is ongoing. Total revenue for its second quarter was $4.4 billion while net income was $2.8 billion. With its impressive financials, would you consider MRNA stock a buy?
[Read More] Best Stocks To Buy Right Now? 5 Aerospace Stocks To Know
Johnson & Johnson
Johnson & Johnson (JNJ) is a multinational corporation that develops medical devices, pharmaceuticals, and consumer packaged goods. With over 130 years of experience, the company is one of the world’s largest and most broadly-based health care companies. Recently, it announced that its coronavirus vaccine is highly effective in preventing severe disease and death from the Delta variant, according to data released from a clinical trial in South Africa. The results from the trial of nearly 480,000 health care workers mark the first real-world test of the company’s single-dose vaccine against the Delta variant. JNJ stock currently trades at $173.21 as of 12:14 p.m. ET.
In late July, the company announced that it had received FDA approval for UPTRAVI, for intravenous use in adult patients with pulmonary arterial hypertension (PAH). The injection is a therapeutic option that will allow patients to avoid short-term treatment interruptions and stay on UPTRAVI therapy. The company also reported strong second-quarter results in July. Firstly, the company posted a strong sales growth of 27.1% to $23.3 billion. Secondly, net earnings for the quarter were $6.27 billion or earnings per share of $2.35, increasing by over 70% during the quarter. All things considered, will you buy JNJ stock?
[Read More] 4 Artificial Intelligence Stocks To Watch Right Now
Pfizer Inc.
Last but not least, we will be taking a look at the earliest name in the coronavirus vaccine race, Pfizer. Thanks to its collaboration with BioNTech (NASDAQ: BNTX) the company remains one of the major players in the vaccine industry now. For a sense of scale, Pfizer reportedly sold $7.8 billion in vaccines throughout the second quarter. On top of that, the company also reported solid figures in its latest quarter fiscal, exceeding Wall Street’s estimates. With its current momentum, Pfizer is currently targeting 2021 vaccine sales of up to $33.5 billion. Notably, this marks a sizable increase from its previous forecast of $26 billion.
With this being the case, it would not surprise me to see investors considering PFE stock now. As it stands, the company’s shares currently trade at $45.41 as of 12:14 p.m. ET. If anything, Pfizer does not seem to be resting on its laurels just yet. For starters, the company is set to supply an additional 200 million doses of its vaccine to the U.S. government.
More than half of which is set to be delivered by the end of the year. At the same time, Pfizer’s Inflammation & Immunology department also presented positive top-line results from medical trials of its scalp hair regrowth treatment, ritlectinib. With the company seemingly firing on all cylinders now, would PFE stock be a top buy for you?
